
ACT Brief: APAC Trial Advantages, Learning From Setbacks, and Sunharbo Stroke Prevention Approval
11/11/2026
0:00
1:41
In today’s ACT Brief, we examine why APAC is attractive for global Phase III programs, how clinical research professionals can turn a failed pivotal trial into a redesigned success, and how FDA approved Sunharbo to reduce recurrent stroke risk.
More episodes from "Applied Clinical Trials"



Don't miss an episode of “Applied Clinical Trials” and subscribe to it in the GetPodcast app.








